A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients

Open Access
Publisher Website
Google Scholar
Abstract
The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV-RTV 1200/200 mg q.d. regimen were studied in a human immunodeficiency virus (HIV)—infected population. The geometric least-square mean ratio (90% confidence interval) of steady-state trough concentrations, compared with that of the amprenavir 1200 mg b.i.d. regimen, was 6.08 (4.94–7.49) for the twice-daily APV-RTV regimen, and it was 4.19 (2.90–6.08) for the daily APV-RTV regimen. The regimens were well tolerated, which supports APV-RTV as an option for twice-daily or daily therapy for HIV.